HCP-event, HCP-event 2024 NCSM Breaking Barriers In Cancer 11 Aug View Fullscreen lungadmin Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial ALK Positive NSCLC Booklet Launch
